In 2022, the pharmaceutical industry has begun to usher in a wave of drug withdrawals

Recently, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding Procurement Network issued the "Notice on Announcement of Some Enterprises' Revocation of the Platform for Online Purchase Qualifications"
.
The notice shows that 46 pharmaceutical manufacturers including Ruiyang Pharmaceutical Co.
, Ltd.
have applied for revocation of their eligibility for online purchases on the platform for 113 drug product regulations.
The products of the above-mentioned companies will not be accepted for re-listing within two years after their products are revoked
.
The author was informed that, in addition to the removal of 113 drug product regulations from the Internet, on January 6, the Shanxi Provincial Center for Pharmaceutical and Equipment Bidding and Purchasing also issued the "Notice on Publicizing Some Enterprises' Application for Revocation of the Platform for Online Purchase Qualifications"
.
According to the notice, 44 drug product regulatory applications were withdrawn from the Internet, all of which were proprietary Chinese medicines, involving 19 Chinese medicine companies
.
According to the notice, the drugs withdrawn at that time included Qianliejiedu Capsules, Xiaoaiping Tablets, Dabuyin Pills, Ginkgo Biloba Leaf, and Lemahui Injection
.
There are 19 Chinese medicine companies involved, including Kangyuan Pharmaceuticals, Hunan Huana Pharmaceuticals, Shuangqi Pharmaceuticals, Kedi Pharmaceuticals, Huqingyutang Pharmaceuticals, and Tangwei Pharmaceuticals
.
In addition to Shanxi Province, in fact, many provinces have recently issued notices for withdrawing medicines from the Internet
.
For example, on January 18, the Shaanxi Provincial Public Resources Trading Center issued a notice on the dynamic adjustment of drug listings on the Internet
.
The content of the notice shows: According to the "Implementation Plan for the Dynamic Adjustment of Drug Sunshine Internet Listing", 30 drugs have been withdrawn from the Internet, including Qiye Shen'an Tablets, Cetirizine Hydrochloride Capsules, Berberine Hydrochloride Tablets, Naloxone Hydrochloride Injection, Red Hua injection, Xiaoyanzhike tablets, Yankening tablets Xinshenghua granules, Shedan Chuanbei liquid, Ganmaozhike granules,
etc.
The companies involved include Yunnan Botanical Pharmaceutical Co.
, Ltd.
, Wuhan Taifu Pharmaceutical Co.
, Ltd.
, and Yabao Pharmaceutical
.
It is worth noting that 10 varieties of Yunnan Botanical Pharmaceutical Co.
, Ltd.
have been withdrawn, and these withdrawn varieties are all Chinese patent medicines
.
In addition, on January 18, the Hunan Provincial Medical Insurance Bureau website released the "Notice on Price Correction and Price Limiting Listing of Some Drugs", as well as a list of generic drug names, and decided to compare the price differences within the same listing catalog.
10 drugs, such as famotidine, which are too large (especially the large difference in prices in different periods), obviously inconsistent in price and quality, have many complaints to each other, and were reported to be inflated by real-name reports, have undergone price corrections and price-limited listings
.
On the previous day, the Sichuan Provincial Pharmaceutical Equipment Recruitment and Procurement Center also removed 186 products that concealed the lowest listing price/bidding price (Tibet price) in the country
.
Since last year, more and more regions have implemented monitoring of drug prices, and a new wave of price adjustments and withdrawals from the Internet is blowing across the country
.
On the whole, with the continuous advancement of the centralized drug procurement organized by the state, the competition among pharmaceutical companies has become more and more intense, and affected by this, the withdrawal of drugs from the Internet has also become the norm
.
Among them, Chinese patent medicines and Chinese medicine injections have gradually become the bulk of the withdrawal
.
In this regard, the industry believes that in the future, with the normalization of centralized drug procurement organized by the state, more and more drugs that have not been consistently evaluated, and drugs that do not meet the requirements of centralized procurement will be withdrawn from the network more frequently
.
In this context, the company's price decision-making ability, as well as its strategic decision-making ability and product layout ability will be increasingly tested
.
In the future, pharmaceutical companies can only better respond to changes in the pharmaceutical market by innovating and expanding their product line layout to further enhance their competitiveness
.